Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07635849

Randomized Clinical Trial of Artificial Tears With and Without Preservatives in Patients With Dry Eye Disease

Dry Eye Disease (DED) is a common, chronic ocular surface disorder characterized by tear film instability, ocular discomfort, and visual disturbance. Artificial tears are the first-line treatment for DED; however, many formulations contain preservatives such as benzalkonium chloride (BAK) and stabilized oxychloro complex (SOC) which may cause ocular surface toxicity with long-term use. Preservative-free artificial tears are considered safer alternatives, but comparative clinical evidence from Nepal is limited. This study aims to compare the clinical efficacy and safety of preservative-free versus preserved carboxymethylcellulose (CMC) artificial tears in patients with Dry Eye Disease. This will be a hospital-based, randomized, double-blinded controlled clinical trial conducted in the ophthalmology outpatient department of a tertiary care hospital in Nepal. A total of 80 adult patients diagnosed with Dry Eye Disease will be enrolled and randomly allocated in a 1:1 ratio to receive either preservative-free CMC artificial tears or preserved CMC artificial tears for a duration of eight weeks. Participant, investigators, outcome assessors and data analysts will remain blinded to minimize assessment bias. Baseline assessments will include the Ocular Surface Disease Index (OSDI) questionnaire, Tear Film Break-Up Time (TBUT), Schirmer's test (without anesthesia), and corneal fluorescein staining. These outcomes will be reassessed at four and eight weeks. Safety and tolerability will be evaluated by documenting patient-reported adverse effects. Data will be analyzed using appropriate statistical methods, with a p-value of less than 0.05 considered statistically significant. The study is expected to demonstrate superior safety and improved ocular surface outcomes with preservative-free artificial tears compared to preserved formulations. Findings from this research will provide local evidence to guide rational prescribing practices and improve the management of Dry Eye Disease in Nepal.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Pokhara Academy of Health Sciences

Pokhara, Gandaki, 33700, Nepal

Location contact

Damodar Sharma, MBBS, MD

PRINCIPAL_INVESTIGATOR

Phanindra Prasad Poudel, Msc, PhD

CONTACT

[email protected]

+977-9846115569

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Clinical diagnosis of Dry Eye Disease (OSDI >13 and TBUT <10 seconds)
  • Willingness to provide written informed consent

Exclusion criteria

  • Contact lens use
  • Active ocular infection or inflammation
  • History of ocular surgery within the past 6 months
  • Use of systemic immunosuppressive therapy

Treatment and study plan

Carboxy methyl cellulose

Drug

A total of 40 adult patients diagnosed with Dry Eye Disease will be enrolled and randomly allocated in a 1:1 ratio to receive preserved CMC artificial tears for a duration of eight weeks.

Other names: preserved CMC

Preservative free Carboxy methyl cellulose

Drug

A total of 40 adult patients diagnosed with Dry Eye Disease will be enrolled and randomly allocated in a 1:1 ratio to receive preservative-free CMC artificial tears for a duration of eight weeks.

Other names: preservative-free CMC

Primary outcomes

  1. Ocular Surface Disease Index (OSDI) Score

    Time frame: From enrollment to the end of treatment at 8 weeks

    Ocular Surface Disease Index (OSDI) Score. The OSDI is a 12-item questionnaire that assesses dry eye symptoms and their impact on vision-related functioning. Total scores range from a minimum of 0 to a maximum of 100. Higher scores indicate more severe dry eye symptoms and a worse outcome.

Secondary outcomes

  1. Tear Film Break-Up Time (TBUT)

    Time frame: From enrollment to the end of treatment at 8 weeks

    Tear Film Break-Up Time (TBUT). This measures the time elapsed in seconds between a complete blink and the appearance of the first dry spot on the cornea. It does not have a strict maximum value, but a minimum of 0 seconds. Higher values indicate a more stable tear film and a better outcome.

  2. Schirmer's Test (without anesthesia)

    Time frame: From enrollment to the end of treatment at 8 weeks

    This measures basic tear production by placing a paper strip inside the lower eyelid for 5 minutes. It is measured in millimeters (mm) of wetting, with a minimum of 0 mm and a typical maximum of 35 mm. Higher values indicate better tear production and a better outcome.

  3. Corneal Fluorescein Staining Score

    Time frame: From enrollment to the end of treatment at 8 weeks

    Corneal Fluorescein Staining Score using the Oxford Grading Scheme. This scale assesses the severity of damage to the surface of the eye. The total score ranges from a minimum of 0 to a maximum of 15. Higher scores indicate greater damage to the cornea and a worse outcome.

Other outcomes

  1. Safety and Tolerability (Adverse Effects)

    Time frame: From enrollment to the end of treatment at 8 weeks

    Patient-reported adverse effects will be systematically documented throughout the trial to evaluate the safety and tolerability of the respective artificial tear formulations

Study contacts

Contact information is provided by the study sponsor or research team.

Damodar Sharma, MBBS, MD

CONTACT

[email protected]

+977-9856022583

Jamuna Gurung, MBBS, MD

CONTACT

[email protected]

+977-9860314317

Sponsors and collaborators

Lead sponsor

Pokhara Academy of Health Sciences, Western Regional Hospital

Other Gov

Registry information

Official study title

Comparative Effectiveness of Artificial Tears With and Without Preservatives in Patients With Dry Eye Disease: A Randomized Clinical Trial

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 9, 2026
Registry last updated
Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.